Clinical trials: Papulopustular Rosacea
- Condition Papulopustular Rosacea
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Facial Papulopustular Rosacea
A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
The primary objectives of this study are to determine the efficacy and safety of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea.
- Trial name
- NCT03142451
- Testing
- FMX103 minocycline foam 1.5%, Vehicle foam
- Where
- 54 sites in United States
- Volunteers
- 751 people
- Sponsor
- Vyne Therapeutics Inc.
Facial Papulopustular Rosacea
A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
The primary objectives of this study are to determine the efficacy and safety of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea.
- Trial name
- NCT04608500
- Testing
- FMX103 minocycline foam 1.5%, Vehicle foam
- Where
- 46 sites in United States
- Volunteers
- 771 people
- Sponsor
- Vyne Therapeutics Inc.
Papulopustular Rosacea (PPR)
Phase 3 Papulopustular Rosacea Study
The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be…
- Trial name
- NCT01493687
- Testing
- CD5024, Azelaic acid 15% Gel
- Where
- 50 sites in United States, Canada
- Volunteers
- 683 people
- Sponsor
- Galderma R&D
Erythematotelangiectatic Rosacea, Papulopustular Rosacea
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
A single center prospective, randomized, controlled split face study comparing a 532nm KTP laser with a 595nm PDL for the treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea.
- Trial name
- NCT02268474
- Testing
- 532nm KTP Laser vs 595nm Pulse Dye Laser
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Cutera Inc.
Rosacea
Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle
This study evaluates the safety and efficacy of once-daily application of CLS001 topical gel compared to vehicle gel in subjects with severe papulopustular rosacea.
- Trial name
- NCT02547441
- Testing
- CLS001 (Omiganan), Vehicle
- Where
- 41 sites in United States, Australia and 7 more
- Volunteers
- 463 people, healthy volunteers welcome
- Sponsor
- Maruho Co., Ltd.
Papulopustular Rosacea
Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea
Subjects with moderate papulopustular rosacea will be treated either with azelaic acid 15% gel topically plus an anti-inflammatory dose of doxycyline (40mg) daily or with metronidazole 1% gel topically once daily plus an…
- Trial name
- NCT00855595
- Testing
- Azelaic acid (Finacea, BAY39-6251), Metronidazole (Metrogel), Doxycycline (Oracea)
- Where
- 17 sites in United States
- Volunteers
- 207 people
- Sponsor
- LEO Pharma
Papulopustular Rosacea
Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
The purpose of this study is to characterize rosacea patients', being treated with Oracea, perception through visual analog scale reporting.
- Trial name
- NCT01872715
- Testing
- Oracea
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Galderma R&D
Rosacea
Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle
This study evaluates the safety and efficacy of once-daily application of CLS001 topical gel compared to vehicle gel in subjects with severe papulopustular rosacea.
- Trial name
- NCT02576860
- Testing
- CLS001 (Omiganan), Vehicle
- Where
- 47 sites in United States, Australia and 7 more
- Volunteers
- 263 people, healthy volunteers welcome
- Sponsor
- Maruho Co., Ltd.
Papulopustular Rosacea
A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea
The primary objective is to show that open-label extended treatment with FMX103 1.5%, for up to an additional 40 weeks, is safe and well tolerated.
- Trial name
- NCT03276936
- Testing
- FMX103 1.5%
- Where
- 79 sites in United States
- Volunteers
- 504 people
- Sponsor
- Vyne Therapeutics Inc.
Papulopustular Rosacea
A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea
To assess the efficacy and safety of S5G4T-1 compared to S5G4T-1 vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.
- Trial name
- NCT03564119
- Testing
- S5G4T-1, S5G4T-2
- Where
- United States
- Volunteers
- 372 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Papulopustular Rosacea
Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea
This study will investigate the safety and efficacy of a new formulation of an existing medication for the treatment of papulopustular rosacea. The study will test the active ingredient plus foam against foam alone.
- Trial name
- NCT01025635
- Testing
- Azelaic acid foam 15%, Vehicle foam
- Where
- 20 sites in United States
- Volunteers
- 401 people
- Sponsor
- LEO Pharma
Papulopustular Rosacea
Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea
The purpose of this study is to assess the safety and efficacy of azelaic acid (AzA) foam, 15% topically applied twice daily for 12 weeks in subjects with papulopustular rosacea compared to its vehicle.
- Trial name
- NCT01555463
- Testing
- Azelaic acid foam, 15% (BAY39-6251), Vehicle foam
- Where
- 49 sites in United States
- Volunteers
- 961 people
- Sponsor
- LEO Pharma
Papulopustular Rosacea
A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
To assess the efficacy and safety of S5G4T-1 compared to its vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.
- Trial name
- NCT03448939
- Testing
- S5G4T-1, S5G4T-2
- Where
- United States
- Volunteers
- 361 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Rosacea
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
The objective of this study is to determine the clinical effects of doxycycline 40 mg (30 mg immediate release and 10 mg delayed release beads) capsules (Oracea®) as compared to placebo in the skin of adults with papulopustular…
- Trial name
- NCT01308619
- Testing
- Doxycycline
- Where
- 10 sites in United States
- Volunteers
- 170 people
- Sponsor
- Galderma R&D
Rosacea
Effect of CD07805/47 Gel in Rosacea Flushing
Phase 2a study to assess the efficacy and safety of CD07805/47 0.5% gel in the prevention of the flush of rosacea.
- Trial name
- NCT02300129
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are…
- Trial name
- MVOR-1 (NCT05296629)
- Testing
- DFD-29, Doxycycline
- Where
- 27 sites in United States
- Volunteers
- 323 people
- Sponsor
- Journey Medical Corporation
Moderate to Severe Papulopustular Rosacea
Clinical Endpoint Study of Ivermectin 1% Cream
A randomized, double-blind, placebo-controlled, parallel-design, multiple-site clinical study to evaluate the therapeutic equivalence and safety of ivermectin cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (ivermectin)…
- Trial name
- NCT02840461
- Testing
- Ivermectin Cream, 1%
- Where
- United States
- Volunteers
- 630 people
- Sponsor
- Actavis Inc.
Papulopustular Rosacea
CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study
Study objectives: To compare efficacy and safety of Ivermectin 1% cream versus metronidazole 0.75% cream in subjects with papulopustular rosacea after 16-week topical treatment.
- Trial name
- ATTRACT (NCT01493947)
- Testing
- Ivermectin 1% cream, Metronidazole 0.75% cream
- Where
- 60 sites in Bulgaria, Czechia and 8 more
- Volunteers
- 962 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea
This exploratory study is being performed to determine whether a new form formulation of azelaic acid 15% is effective in the treatment of papulopustular rosecea.
- Trial name
- NCT00617903
- Testing
- Azelaic acid, Vehicle foam
- Where
- 7 sites in United States
- Volunteers
- 83 people
- Sponsor
- LEO Pharma
Papulopustular Rosacea
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are…
- Trial name
- MVOR-2 (NCT05343455)
- Testing
- DFD-29, Doxycycline
- Where
- 24 sites in United States, Germany
- Volunteers
- 330 people
- Sponsor
- Journey Medical Corporation